Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness.

BioDrugs · 2025 · PMC11750907 · PMID 39412713

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Since 2018, both trastuzumab originator and its biosimilars have been used as anti-HER2 agents in Japanese patients, with an increasing trend in biosimilar usage.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.